Sign in

You're signed outSign in or to get full access.

Sanjay Banker

Director at SOND
Board

About Sanjay Banker

Independent director (not classified as independent under Nasdaq rules due to prior employment) at Sonder Holdings Inc. since January 2023; age 50 as of September 25, 2025 . Former President and CFO of Sonder (Jan–Dec 2022), and previously CFO (Jan 2019–Jan 2022) and President (Sep 2020–Jan 2022) of Legacy Sonder; currently CEO of Private Medical (since June 2024). Education: B.S. in Economics (Wharton) and M.B.A. (Harvard Business School) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Sonder Holdings Inc.President & CFOJan 2022–Dec 2022Senior executive role through de‑SPAC integration
Legacy Sonder (pre-Business Combination)CFO; PresidentCFO: Jan 2019–Jan 2022; President: Sep 2020–Jan 2022Led finance and operations pre‑listing
TPG GrowthPartnerMar 2013–Jan 2019Investment leadership
Bain CapitalPrincipalSep 2004–Mar 2013Private equity investing
McKinsey & CompanyEngagement ManagerSep 1996–Aug 2004Strategy consulting

External Roles

OrganizationRoleTenureNotes
Private MedicalChief Executive OfficerJun 2024–presentHigh-end concierge medicine provider

Board Governance

  • Board class and term: Class III director; current term expires at 2027 annual meeting .
  • Independence: Board has determined Mr. Banker is not independent due to former employee status .
  • Committees: No current committee assignments (not listed on Audit, Compensation, Nominating, or Investment Committees) .
  • Attendance: The Board held 7 meetings in 2023; all current members attended ≥75% of Board/committee meetings. In FY 2024, the Board held 22 meetings; all current members attended ≥75% of meetings .

Fixed Compensation

Metric20232024
Fees Earned or Paid in Cash ($)$35,000 $35,000
Advisory/Other Cash Compensation ($)$509,367 (transition advisory agreement $473,680; COBRA $21,134; related tax gross-up $14,553) — (no additional disclosed “other” comp)
Policy ContextStandard non-employee director cash retainer was $35,000 in 2023; increased to $65,000 in Dec 2024 (committee member fees removed; chair retainers increased) Outside Director Compensation Policy updated Dec 2024: $65,000 board retainer; chair retainers: Audit $25,000; Compensation $20,000; Investment $20,000; Nominating $15,000; meeting fee $1,500 beyond 8 meetings/year

Performance Compensation

Equity GrantsGrant DateShares/UnitsGrant Date Fair Value ($)Vesting
Initial RSU grantJan 3, 202312,598 RSUs Included in 2023 total stock awards of $399,966 One-third annually, subject to service
Prorated Annual RSU grantJun 7, 20236,258 RSUs Included in 2023 total stock awards of $399,966 Vests in full at earlier of 1-year or next annual meeting, subject to service
Annual RSU grant (policy)2024— (no equity grants due to Form S-8 issues)
Equity policy changesDec 2024Annual RSU grant value set to $125,000; Board Chair $175,000; non-employee directors not independent receive 50% of equity compensation they would otherwise receive

Performance metrics: Director equity awards are time-based RSUs; no performance metrics disclosed for directors. Executive PSU metrics were introduced in 2025 for executives, not directors .

Other Directorships & Interlocks

CompanyRoleCommittee PositionsNotes
None disclosed (public company boards)No public company directorships disclosed for Mr. Banker

Expertise & Qualifications

  • Finance and investment expertise from TPG Growth and Bain Capital; prior CFO/President roles at Sonder provide deep operating and capital markets knowledge .
  • Strategy and operational experience from McKinsey; current healthcare leadership broadens perspective, but limited industry conflict overlap with hospitality .

Equity Ownership

Metric2024 (older)2025 (newer)
Common Shares Beneficially Owned (Number; %)221,724; 1.9% 246,612; 1.8%
Series A Preferred Beneficially Owned (Number; %)29,000; 0.2% 100,000; <1% (asterisk indicates <1%)
Vested/Exercisable Options (within 60 days)182,266 shares underlying options exercisable within 60 days
RSUs vesting within 60 days49,689 RSUs vesting within 60 days
Direct Common Shares14,657 common shares held directly
Shares pledged as collateralNone disclosed for Mr. Banker (pledging noted only for CEO’s exchangeables in 2024; otherwise no pledging by current directors)

Governance Assessment

  • Independence and committee roles: Mr. Banker is not independent and holds no committee assignments, limiting direct influence over audit, compensation, and nominating processes—this may constrain board checks-and-balances around management oversight .
  • Related-party/executive transition payments: Material advisory and benefit-related payments in 2023 following his transition ($509,367 total) could be perceived as a potential independence concern for a sitting director, even if ordinary-course, warranting monitoring by investors focused on governance rigor .
  • Equity alignment: He holds common stock, vested options, and RSUs; stock ownership guidelines adopted in March 2025 require Outside Directors to hold 4x annual retainer, with 5-year compliance and 50% retention until met; however, as a non-independent director, equity awards are paid at 50% of standard levels per the updated policy .
  • Compliance signals: One administrative error in Section 16 reporting (Form 4) noted for Mr. Banker regarding acquisition of Series A preferred stock; while minor, it indicates operational control gaps that were acknowledged and corrected .
  • Attendance and engagement: Board met frequently (22 meetings in FY 2024); directors attended ≥75%, suggesting baseline engagement, though absence of committee roles limits Mr. Banker’s formal oversight channels .

RED FLAGS

  • Not independent; prior executive status and 2023 transition payments may raise perceived conflicts for investors scrutinizing board independence .
  • Section 16 reporting error (Form 4) for Mr. Banker in 2024 disclosure cycle (reported in 2025 proxy) .

Positive Signals

  • Meaningful equity/option exposure and continuing director service; board adopted formal ownership guidelines and tightened equity award structures in late 2024–2025 .
  • No pledging or hedging permitted under insider trading policy; clawback policy in place .

Notes on Policies Relevant to Alignment and Risk

  • Insider Trading Policy prohibits hedging, pledging, and derivatives; directors must pre-clear trades; 10b5‑1 plans are permitted .
  • Clawback Policy: recovery of incentive-based compensation upon accounting restatement; disclosed and filed as an exhibit .
  • Director Compensation Policy changes: equity grant values standardized; equity for non-independent directors reduced to 50%; cash retainers increased for board and chairs; meeting fees for >8 meetings/year .
All information above is drawn from Sonder’s DEF 14A proxies and 8-K filings:
— 2024 DEF 14A (Nov 8, 2024): Board composition, director bios, independence, director compensation tables and RSU grants, equity plan details, ownership table **[1819395_0001753926-24-001840_g084537_def14a.htm:16]** **[1819395_0001753926-24-001840_g084537_def14a.htm:18]** **[1819395_0001753926-24-001840_g084537_def14a.htm:22]** **[1819395_0001753926-24-001840_g084537_def14a.htm:24]** **[1819395_0001753926-24-001840_g084537_def14a.htm:38]** **[1819395_0001753926-24-001840_g084537_def14a.htm:39]** **[1819395_0001753926-24-001840_g084537_def14a.htm:40]** **[1819395_0001753926-24-001840_g084537_def14a.htm:58]**.
— 2025 DEF 14A (Sep 25, 2025): Updated Board composition, independence, committee structures, stock ownership guidelines, director compensation policy changes, ownership breakdown, Section 16 compliance note **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:16]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:21]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:23]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:25]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:36]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:37]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:39]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:40]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:41]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:50]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:52]** **[1819395_0001819395-25-000120_a2025proxystatementdef14a2.htm:29]**.
— 8‑K (Jul 24, 2023): Executive transitions (context) **[1819395_0001819395-23-000104_son-20230719.htm:1]**.